Express Pharma

COVID treatment: Centre issues revised guidelines on use of drugs and therapies

The revised guidelines continue to recommend Emergency Use Authorisation (EUA) or off-label use of Remdesivir in patients with moderate-to-severe disease and those with no renal or hepatic dysfunction within 10 days of the onset of any symptom